pharmaceuticals
pharmaceuticals Articles
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Published:
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published:
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.
Published:
Last Updated:
America and the rest of the world is getting ready for a vaccine that will help protect public health against the COVID-19 pandemic. The societal impact of the coronavirus has changed many lives, and...
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
Published:
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
Published:
Last Updated:
After Momenta Pharmaceuticals announced that it would be acquired by pharmaceutical giant Johnson & Johnson, the biotechnology company's shares soared on Wednesday.
Published:
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Published:
Principia Biopharma shares jumped to start out the week after it was announced that it would be acquired by Sanofi.
Published:
When Moderna announced a new deal with the U.S. government for its COVID-19 vaccine, it appeared be a case of “sell the news,” because this is ultimately a net positive for the company.
Published:
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
Published:
The world may be focused on COVID-19 this year, but the battle against Alzheimer’s disease continues with no effective treatments. Biogen hopes to remedy that unfortunate situation.
Published:
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
Published: